The "Golden Window" for Menopause and Andropause
Clinical consensus in 2026 emphasizes the "Timing Hypothesis" or the "Golden Window" for starting BHRT. Research indicates that starting therapy at the onset of perimenopause or andropause (male hormone decline) provides the greatest neuroprotective and cardioprotective benefits.
BHRT is no longer used just for "hot flashes." It is now a primary tool for maintaining bone mineral density, muscle mass, and cognitive clarity. By stabilizing hormone levels early, patients in 2026 are successfully mitigating the long-term risks of osteoporosis and age-related metabolic dysfunction.
2 Views